Polymorphisms in the MTHFR gene are associated with breast cancer risk and prognosis in a Chinese population

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3757-3762

  Lu, Qing ^a   Jiang, Ke ^a   Li, Qiong ^a   Ji, Ya Jie ^a   Chen, Wei Li ^a   Xue, Xiao Hong ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Biomarker; Folate; Haplotype; Survival; Susceptibility; Tagging SNP

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHINA; CHINESE; CONTROLLED STUDY; FEMALE; FOLIC ACID BLOOD LEVEL; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; BREAST TUMOR; GENETICS; GENOTYPE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; CHINA; FEMALE; FOLIC ACID; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84929950702     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-3016-4     Document Type: Article

References (20)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 09/10/2014
2. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5:283–98.
3. Brody JG, Rudel RA, Michels KB, Moysich KB, Bernstein L, Attfield KR, et al. Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention? Cancer. 2007;109:2627–34.
4. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013;25:368–87.
5. Rawal R, Bertelsen L, Olsen JH. Cancer incidence in first-degree relatives of a population-based set of cases of early-onset breast cancer. Eur J Cancer. 2006;42:3034–40.
6. Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet. 2007;44:481–4.
7. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22:4632–42.
8. Shahzad K, Hai A, Ahmed A, Kizilbash N, Alruwaili J. A structured-based model for the decreased activity of Ala222Val and Glu429Ala methylenetetrahydrofolate reductase (MTHFR) mutants. Bioinformation. 2013;9:929–36.
9. Izmirli M. A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk. Mol Biol Rep. 2013;40:625–37.
10. Shujuan Y, Jianxing Z, Xin-Yue C. Methylenetetrahydrofolate reductase genetic polymorphisms and esophageal squamous cell carcinoma susceptibility: a meta-analysis of case-control studies. Pak J Med Sci. 2013;29:693–8.
11. Yu L, Chen J. Association of MTHFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: an update meta-analysis based on 51 research studies. Diagn Pathol. 2012;7:171.
12. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.
13. Lin DY, Zeng D, Millikan R. Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol. 2005;29:299–312.
14. Nazki FH, Sameer AS, Ganaie BA. Folate: metabolism, genes, polymorphisms and the associated diseases. Gene. 2014;533:11–20.
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.
16. Gao CM, Tang JH, Cao HX, Ding JH, Wu JZ, Wang J, et al. MTHFR polymorphisms, dietary folate intake and breast cancer risk in Chinese women. J Hum Genet. 2009;4:414–8.
17. Shrubsole MJ, Gao YT, Cai Q, Shu XO, Dai Q, Hébert JR, et al. MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev. 2004;13:190–6.
18. Liang H, Yan Y, Li T, Li R, Li M, Li S, et al. Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case-control studies. Tumour Biol. 2014;35:1695–701.
19. Swartz MD, Peterson CB, Lupo PJ, Wu X, Forman MR, Spitz MR, et al. Investigating multiple candidate genes and nutrients in the folate metabolism pathway to detect genetic and nutritional risk factors for lung cancer. PLoS One. 2013;8:e53475.
20. Chen Y, Ying D, Deng YC AHL, Wang HJ, Ma YQ, et al. Relationship between MTHFR gene polymorphisms and susceptibility of esophageal cancer of Han nationality in Xinjiang. J Toxicol. 2009;23:429–32.